* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 1200 Paul Winter
Gene therapy wikipedia , lookup
Protein moonlighting wikipedia , lookup
Nucleic acid analogue wikipedia , lookup
Gene nomenclature wikipedia , lookup
Vectors in gene therapy wikipedia , lookup
Epigenetics of diabetes Type 2 wikipedia , lookup
Genome evolution wikipedia , lookup
Nutriepigenomics wikipedia , lookup
Population genetics wikipedia , lookup
Gene therapy of the human retina wikipedia , lookup
Expanded genetic code wikipedia , lookup
Designer baby wikipedia , lookup
No-SCAR (Scarless Cas9 Assisted Recombineering) Genome Editing wikipedia , lookup
Epigenetics of neurodegenerative diseases wikipedia , lookup
Oncogenomics wikipedia , lookup
Saethre–Chotzen syndrome wikipedia , lookup
Cell-free fetal DNA wikipedia , lookup
Site-specific recombinase technology wikipedia , lookup
Neuronal ceroid lipofuscinosis wikipedia , lookup
Helitron (biology) wikipedia , lookup
Therapeutic gene modulation wikipedia , lookup
Artificial gene synthesis wikipedia , lookup
Microevolution wikipedia , lookup
Genetic code wikipedia , lookup
Genetics of Inherited Bleeding Disorders Dr Paul Winter N. Ireland Haemophilia Centre Belfast City Hospital Inherited Bleeding Disorders A group of inherited diseases Abnormal and prolonged bleeding - Haemophilia: Coagulation defect, deficiency of Factor VIII/IX - VWD: Defect in platelet adhesion, deficiency of Von Willebrand Factor - Rare coagulation factor deficiencies How Blood Clots • Coagulation System makes Fibrin • Forms a supporting network around the platelet plug • Strengthens the clot • Seals the damaged area of the blood vessel • Prevents further blood loss • Coagulation System is a series of linked enzyme reactions • Enzymes are proteins called Clotting Factors • Each Factor given a number (Roman Numerals) • Factor VIII and Factor IX are two of the most important clotting factors Inheritance of Haemophilia Inheritance is X-Linked - males affected - females may be carriers Haemophilia A: ~1/10,000 males Haemophilia B: ~1/30,000 males Haemophilia Inheritance XX XY XY XY XX XX Mother is a Carrier: 50% of sons have Haemophilia 50% of daughters are Carriers Important to identify female carriers for Genetic Counselling Haemophilia A Lack of Factor VIII in plasma Range of clinical severity: Severe/moderate/mild Severity related to Factor VIII activity (FVIII:C) - Severe: 0-2% - Moderate: 2-5% - Mild: 5-30% Haemophilia A • Lack of Factor VIII in plasma is caused by mutations in the gene that makes the Factor VIII protein • F8 gene is located at the tip of the X chromosome What is a Gene? A piece of DNA that contains all the information needed to make a protein Human Beings have 35,000 genes. Genes are spread out along the chromosomes Each gene makes a different protein Proteins do lots of important jobs in the cell DNA Linear molecule, very long Double Helix A, G, C, T (bases) DNA Sequence contains information needed to make a protein Proteins Do all the jobs that need done in the cell Proteins are strings of amino acids 30 different amino acids Each amino acid encoded by 3 DNA bases (codon) AGC = Arginine TTC = Phenylalanine GTC = Valine F8 Gene • F8 Gene is very large – 186,000 bases • Gene is split into Exons and Introns • The 26 exons encode the 2332 amino acid sequence of the Factor VIII protein • The 26 exons cover 8,000 bases. • Haemophilia A is caused by a mutation of just one base Mutation Screening Males with Haemophilia are routinely screened to identify their F8 mutation Two Purposes: 1. Confirm the diagnosis and the severity 2. Allows screening of related females who may be carriers and at risk of having an affected male child Identifying F8 Mutations 1. Obtain blood sample from male with Haemophilia 2. Extract DNA sample 3. Isolate his F8 Gene (PCR) 4. Determine the DNA sequence of his F8 Gene 5. Compare patient and normal sequence 6. Look for a difference (Mutation) What is a Mutation? A change in the DNA sequence of a gene that causes an inherited disease Two types of mutation: 1. Point mutations: a single base is changed 2. Gross mutation: a change involving a large piece of DNA sequence (eg: deletion mutation) Point Mutations Three types of Point Mutation cause Haemophilia: 1. Missense Mutations 2. Nonsense Mutations 3. Frameshift Mutations Missense Mutations Missense mutation: base change alters the amino acid encoded at that point G>A mutation: AGC>AAC: Serine>Asparagine C>T mutation: CGT>TGT: Arginine>Cysteine Changing the amino acid alters the biological activity of the protein Usually associated with mild Haemophilia Nonsense Mutations 2. Nonsense Mutations 64 codons encode 30 amino acids Three codons act as a signal to indicate the end of the gene during protein synthesis STOP codons: TGA, TAA and TAG A nonsense mutation is a base change that creates a new STOP codon C>T: CGA>TGA: Arginine>STOP C>A: TCA>TAA: Serine >STOP Nonsense Mutations Start Codon Stop Codon Nonsense mutations create a new STOP codon in the middle of the gene Protein synthesis stops too early A shortened protein is produced (inactive) Usually causes severe Haemophilia Frameshift Mutations 3. Frameshift mutations: Caused by the insertion or deletion of a base Changes the order of the codons in the gene (reading frame) ATT CAG GCA GAA ATA GTA TTT AGA GGG I Q A E I V F R G ATT CAG GTC AGA AAT AGT ATT TAG AGG G I Q V R N V I STOP Frameshift Mutations A different set of amino acids is read after the inserted (or deleted) base Biological activity of the protein is lost Usually causes severe Haemophilia Mutations That Cause Haemophilia are Very Diverse Unique F8 Mutations (n = 2015) Insertions Large Deletions Missense 983 Nonsense 208 Splice 158 Small Deletion 357 Large Deletion 255 Small Deletions Insertion 146 Missense Splice Nonsense Missense Mutation F8 Exon 19 G to A point mutation at nucleotide 6089 Changes Serine 2030 to Asparagine Serine 2030 is highly conserved Sister of patient is heterozygous carrier of the same mutation Carrier Haemophilia A Nonsense Mutation F8 Exon 24 C to T Point mutation at nucleotide 6682 Changes Arginine 2228 (CGA) to a STOP codon (TGA) Premature termination of translation gives shortened protein (unstable) Patient has Severe Haemophilia A Patient’s sister is heterozygous carrier of same mutation Carrier Severe Haemophilia A Frameshift Mutation Single base (A) deleted at nucleotide 3637 (8 A’s instead of 9) Reading frame changes at codon 1213 Normal sequence: ATT CAG GAA GAA ATA GAA I Q E E I E Mutated sequence: TTC AGG AAG AAA TAG F R K K STOP Patient’s sister is heterozygous carrier of the same mutation. Deletion of a single base on one allele causes sequences to be out of phase. 60% have 1 of 3 F8 mutations Von Willebrand Disease First Described by the Finnish Physician, Dr Eric von Willebrand in 1926 In 1926, Erik von Willebrand published an article describing a bleeding disorder he had first observed in some members of a family from the Aland islands The index case was a 5-year old girl who he documented as having a series of lifethreatening bleeding episodes. At the age of 14 years, she subsequently bled to death during her fourth menstrual period. Von Willebrand subsequently studied 66 members of the same family and found that 23 of them had symptoms of the same type. Von Willebrand Disease Most common IBD in Humans Variable and mostly mild bleeding tendency Inherited deficiency of Von Willebrand Factor (VWF) Caused by VWF gene mutations (usually) Inheritance of VWD VWF/VWF VWF/ VWF VWF/VWF VWF/VWF VWF/VWF VWF/VWF -Inheritance different from Haemophilia -Males and Females affected -Autosomal Dominant: only one defective gene needs to be inherited for a person to have the disease -50% of children of a parent with VWD will have VWD themselves Bleeding Symptoms in VWD Distinct from haemophilia Skin and mucous membranes affected: easy bruising, epistaxis, menorrhagia, excessive bleeding from minor wounds, dental extractions, surgery, childbirth, oral bleeding, GI bleeding Unlike haemophilia, musculoskeletal bleeding (haemarthroses, muscle haematomas) is rare Serious bleeding only for severe forms (type 3 VWD). Von Willebrand Factor VWF is a large plasma protein Binding sites for FVIII, collagen and platelets Important role in blood clotting Mediates platelet adhesion and aggregation VWF Multimers - VWF synthesised in endothelial cells and megakaryocytes - Exists as a series of polymer chains called Multimers - Multimer structure is important for role of VWF in blood clotting - VWF stored in granules in platelets and endothelial cells - VWF multimers released into plasma in response to blood vessel injury 1. 2. 3. 4. 5. Vessel Damage exposes subendothelium to blood VWF binds to collagen Gp1b binding site on VWF becomes exposed VWF binds platelets via Gp1b Platelets adhere to damaged area VWF Protects Factor VIII VWF binds Factor VIII in plasma Protects FVIII from degradation No VWF binding: Factor VIII has short half life How Common is VWD? Plasma VWF ref range: 50-200 IU/mL 1% of the population have a level <50IU/mL Clinically significant VWD only seen in 1:8,000 (0.125%) VWF and Bleeding Risk As VWF levels get lower, the risk of bleeding increases but relationship is not strong until the VWF level is very low Mild bleeding is common in healthy population and may be due to factors other than VWF level Diagnosis of VWD cannot be made only on the basis of low plasmaVWF levels Plasma VWF levels Vary Widely Levels affected by genetic and acquired factors Blood group is major genetic influence. Group O 25% lower the Non-O Acquired factors: Age, Exercise, Menstrual Cycle, Thyroid Function Levels increase with age: 6%/decade after 40 Diagnosis of VWD Three Criteria: Laboratory tests indicating a deficiency of VWF PLUS A personal bleeding history A family history of bleeding Lab Tests for VWF VWF: Ag - Measures the amount of VWF protein in plasma - Immunoassay VWF: RiCoF - Measures VWF activity in plasma VWF:RiCoF Test Ristocetin is an obsolete antibiotic Ristocetin binds to VWF and exposes Gp1b binding site VWF can bind platelets spontaneously when ristocetin is present Platelets + ristocetin + Patient plasma Platelet aggregation measured (platelet aggregometer) Aggregation is a measure of VWF activity 3 types of VWD exist Type 1 : Reduced amount of VWF in plasma VWF:Ag andVWF:RCo reduced in parallel Type 2 VWD: Reduced plasma VWF activity VWF:Ag >VWF:RCo (Ratio >2) Type 3 VWD: rare, severe form VWF:Ag andVWF:RCo ~0% Type 2 VWD Type 2A: Loss of the biggest (HMW) multimers, reduced platelet adhesion Type 2B: VWF binds to platelets spontaneously Type 2M: Loss of VWF ability to bind platelets Type 2N: Defective Factor VIII binding Type 1 VWD Reduced plasma VWF levels Two categories of patients: 1. VWF <20 IU/mL associated with: - VWF gene mutation - Significant bleeding - Strong family history of bleeding 75% of mutations are missense Mutations cause secretion failure or rapid clearance from blood Type 1 VWD 2. VWF levels of 30-50 IU/mL - Up to 1% of population - Less than 50% have a VWF gene mutation - Personal and family bleeding history are less convincing - VWF levels alone are not sufficient for a diagnosis of VWD - Levels should be seen as a modest risk factor for bleeding Summary VWD is the most common IBD in humans Results in a mostly mild bleeding tendency that affects males and females Diagnosis requires an assessment of VWF levels in conjunction with a personal and family bleeding history DNA testing is a useful tool to confirm diagnosis Thank you for listening